CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
癌症细胞治疗进展：载体设计与基因组编辑
英文原题：Advances in cellular therapy for cancer: vector design and genome editing.
查看英文原题
Advances in cellular therapy for cancer: vector design and genome editing.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
2025年，细胞治疗领域持续取得科学进展，CAR-T 细胞治疗产品的商业版图进一步扩大，同时受制造成本制约，也出现了显著的战略收缩。该领域还受益于近期T细胞亚群命名体系向基于功能和状态的转变，使得CAR-T 细胞产品能够被更精确地表征。我们重点介绍五项关键进展，包括体内CAR生成、下一代基因组工程，以及AI引导的抗体发现平台在细胞免疫治疗中不断扩展的潜力。
展开英文摘要原文
The year 2025 saw continued scientific progress in cell therapy and further commercial expansion of CAR T-cell therapeutics, alongside notable strategic contractions driven largely by manufacturing cost constraints. The field also benefited from the recent transition in T-cell subset nomenclature toward function- and state-based definitions, enabling more precise characterization of CAR T-cell products.
We highlight five key advances, including in vivo CAR generation, next-generation genome engineering and the expanding potential of AI-guided antibody discovery platforms for cellular immunotherapy.
论文信息
- 作者
- McLellan AD、Dobson LJ、Marron PW、Pe KC
- 单位
- Department of Microbiology & Immunology, The University of Otago, Dunedin, New Zealand.
- 文献类型
- 综述
- 期刊
- Immunology and cell biology2026 May
- 原文标识
- PubMed 41947579 · DOI 10.1111/imcb.70111